Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
You may also be interested in...
The sponsors of six drugs that are nearing the end of the regulatory review cycle in the EU could this week be asked to explain why the European Medicines Agency should recommend approving their products.
The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.